Description
The National Cancer Institute (NCI) is re‑issuing a Notice of Funding Opportunity (NOFO) for Specialized Programs of Research Excellence (SPOREs) focused on human cancers. The program funds P50 Research Center Grants that support investigator‑initiated, translational research aimed at improving prevention, early detection, diagnosis, and treatment of organ‑specific or highly related groups of cancers. Applications may be jointly funded with the National Institute of Dental and Craniofacial Research (NIDCR). Up to 12 awards are anticipated, with an estimated total funding envelope of $25 million. Projects must be translational, based on human biology, and must achieve a human clinical endpoint within the grant period. The award period is expected to begin June 11 2027, with the award decision by June 4 2027. Eligibility includes a broad range of U.S. public and private entities (excluding foreign organizations).
• Funding mechanism: P50 Specialized Center Grant (grant)
• Estimated total funding: $25 M; average award ~ $2 M
• Anticipated number of awards: 12
• Application deadline: Sep 25 2029 (opens Oct 14 2026)
• Project start: Jun 11 2027; award date: Jun 4 2027
• Required deliverables: annual RPPR, data‑management & sharing plan, clinical trial metrics, final close‑out reporting
• Eligible applicants: U.S. state, local, tribal, higher‑education, nonprofit, for‑profit, and other government entities (foreign entities ineligible)
• Contact for scientific questions: Translational Research Program, NCI ([email protected])